Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | METAP2 | P50579 | 1/20 | 0.67 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.67 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.67 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | NSD2 | O96028 | 2/20 | 0.61 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.61 |
| ▸ | CFD | P00746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984940 | 1.00 | KMT2A (1.00) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL11901003 | 0.94 | KMT2A (0.89) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL31680569 | 0.94 | KMT2A (0.89) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL12700348 | 0.90 | APEX1 (0.87) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL6357013 | 0.88 | KMT2A (1.00) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL16127956 | 0.88 | APEX1 (0.84) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL6160362 | 0.88 | KMT2A (0.78) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL7823453 | 0.88 | APEX1 (0.84) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL20538849 | 0.88 | KMT2A (0.78) | KMT2AAPEX1CYP2C19CYP1A2USP2 | |
| SCHEMBL6720193 | 0.87 | KMT2A (0.77) | KMT2AAPEX1CYP2C19CYP1A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-01-29 | — | — | US | disclosed |
| US-8859620-B2 | Phthalanilate compounds and methods of use | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859620-B2 | Phthalanilate compounds and methods of use | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | University of Nortre Dame du Lac | 2012-09-13 | — | — | US | disclosed |
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | University of Nortre Dame du Lac | 2012-09-13 | — | — | US | disclosed |
| WO-2011026107-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2011-03-03 | — | — | WO | disclosed |
| US-5847155-A | Aromatic pyrrolidine amide prolyl endopeptidase inhibitors | PFIZER INC (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0536163-A1 | AROMATIC PYRROLIDINE AND THIAZOLIDINE AMIDES | PFIZER INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1991018891-A1 | AROMATIC PYRROLIDINE AND THIAZOLIDINE AMIDES | PFIZER INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| US-4435567-A | REACTING AN AMINE WITH AN N-CARBAMOYL BENZOIC ACID SULFIMIDE | CHINOIN GYOGYSZER ES VESGYESZETI TERMEKEK GYARA R. T. (HU) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | KMT2A 1142/4885APEX1 709/4885CYP2C19 362/4885 |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, BMP2 | KMT2A 3000/4885APEX1 4071/4885CYP2C19 4864/4885 |
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | KMT2A 1142/4885APEX1 709/4885CYP2C19 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.